Khan Osman, Riazi Shahla, Hu Xinqun, Song Jian, Wade James B, Ecelbarger Carolyn A
Department of Medicine, Georgetown University, Washington, DC 20057-1412, USA.
Am J Physiol Renal Physiol. 2005 Aug;289(2):F442-50. doi: 10.1152/ajprenal.00335.2004. Epub 2005 Apr 5.
Previously, we showed an increase in protein abundance of the renal thiazide-sensitive Na-Cl cotransporter (NCC) in young, prediabetic, obese Zucker rats relative to lean age mates (Bickel CA, Verbalis JF, Knepper MA, and Ecelbarger CA. Am J Physiol Renal Physiol 281: F639-F648, 2001). To test whether this increase correlated with increased thiazide sensitivity (NCC activity) and blood pressure, and could be modified by insulin-sensitizing agents, we treated lean and obese Zucker rats (9 wk old) with either a control diet or this diet supplemented with 3 mg/kg body wt rosiglitazone (RGZ), a peroxisomal proliferator-activated receptor subtype gamma agonist and potent insulin-sensitizing agent, for 12 wk (n = 9/group). The rise in blood pressure, measured continuously by radiotelemetry, was significantly blunted in the RGZ-treated obese rats. Similarly, blood glucose and urinary albumin were markedly decreased in these rats. RGZ-treated rats whether lean or obese excreted a NaCl load faster but excreted less sodium in response to hydrochlorothiazide, applied as a novel in vivo measure of NCC activity. Obese rats had increased renal protein abundance and urinary excretion of NCC; however, this was not significantly reduced by RGZ (densitometry in cortex homogenate - %lean control): 100 +/- 9, 93 +/- 4, 124 +/- 9, and 141 +/- 14 for lean control, lean RGZ, obese control, and obese RGZ, respectively. Subcellular localization, as evaluated by confocal microscopy and immunoblotting following differential centrifugation, of NCC was not different between rat groups. Overall, RGZ reduced blood pressure and thiazide sensitivity; however, the mechanism(s) did not seem to involve a decrease in NCC protein abundance or cellular location. Decreased NCC activity may have contributed to the maintenance of normotension in RGZ-treated obese rats.
此前,我们发现,相较于同龄瘦型 Zucker 大鼠,年轻的糖尿病前期肥胖 Zucker 大鼠肾脏中噻嗪类敏感型 Na-Cl 共转运体(NCC)的蛋白质丰度有所增加(Bickel CA、Verbalis JF、Knepper MA 和 Ecelbarger CA。《美国生理学杂志:肾脏生理学》281 卷:F639 - F648,2001 年)。为了测试这种增加是否与噻嗪类敏感性增加(NCC 活性)和血压升高相关,以及是否可被胰岛素增敏剂改变,我们用对照饮食或补充了 3 mg/kg 体重罗格列酮(RGZ)的饮食(一种过氧化物酶体增殖物激活受体γ亚型激动剂和强效胰岛素增敏剂)对瘦型和肥胖 Zucker 大鼠(9 周龄)进行了 12 周的治疗(每组 n = 9)。通过无线电遥测连续测量的血压升高在接受 RGZ 治疗的肥胖大鼠中明显减弱。同样,这些大鼠的血糖和尿白蛋白明显降低。无论瘦型还是肥胖型,接受 RGZ 治疗的大鼠排泄 NaCl 负荷更快,但对作为 NCC 活性新的体内测量指标应用的氢氯噻嗪反应时排泄的钠更少。肥胖大鼠肾脏中 NCC 的蛋白质丰度和尿排泄增加;然而,RGZ 并未使其显著降低(皮质匀浆的光密度测定 - 相对于瘦型对照的百分比):瘦型对照、瘦型 RGZ、肥胖型对照和肥胖型 RGZ 分别为 100±9、93±4、124±9 和 141±14。通过共聚焦显微镜和差速离心后的免疫印迹评估的 NCC 亚细胞定位在大鼠组之间没有差异。总体而言,RGZ 降低了血压和噻嗪类敏感性;然而,其机制似乎并不涉及 NCC 蛋白质丰度或细胞定位的降低。NCC 活性降低可能有助于维持接受 RGZ 治疗的肥胖大鼠的血压正常。